Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Research & Development (2018 - 2025)

AVITA Medical's Research & Development history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 17.34% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $20.8 million, up 2.36%, while the annual FY2025 figure was $20.8 million, 2.35% up from the prior year.
  • Research & Development reached $5.7 million in Q4 2025 per RCEL's latest filing, up from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.8 million in Q4 2023 to a low of $3.1 million in Q2 2022.
  • Average Research & Development over 5 years is $4.6 million, with a median of $4.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 100.21% in 2023, then crashed 30.95% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.4 million in 2021, then fell by 0.27% to $3.4 million in 2022, then skyrocketed by 100.21% to $6.8 million in 2023, then decreased by 28.31% to $4.8 million in 2024, then grew by 17.34% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Research & Development are $5.7 million (Q4 2025), $3.7 million (Q3 2025), and $5.1 million (Q2 2025).